Biolegend, 135231, Brilliant Violet 711™ anti-mouse CD279 (PD-1) Antibody, 50μg

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.
50μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.
Application References(PubMed link indicates BioLegend citation): Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block) Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block) Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Deák P, et al. 2022. Cell Rep. 41:111563. PubMed Whyte CE, et al. 2022. Curr Protoc. 2:e589. PubMed Lee K, et al. 2023. JCI Insight. 8:. PubMed Prasad S, et al. 2023. iScience. 26:106628. PubMed Schnell A, et al. 2021. Cell. 184:6281. PubMed Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed Hill DL, et al. 2021. Elife. 10:. PubMed Dong L, et al. 2021. Cancer Cell. . PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed Cribioli E, et al. 2022. Front Immunol. 13:976628. PubMed Yin Q, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed Fu X, et al. 2020. Aging (Albany NY). 12:15656. PubMed Gabriel SS, et al. 2021. Immunity. 54(8):1698-1714.e5. PubMed Li C, et al. 2020. Immunity. 52(1):201-202. PubMed Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed Pasciuto E, et al. 2020. Cell. 182:625. PubMed Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed Fedele C, et al. 2021. J Exp Med. 218: . PubMed Alterauge D, et al. 2020. Cell Rep. 33:108232. PubMed Jacobs L, et al. 2022. Cancer Gene Ther. 29:984. PubMed
RRID: AB_2566158 (BioLegend Cat. No. 135231)
Structure: A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution: Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.
Function: Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor: B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type: B cells, T cells
Biology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Nishimura H, et al. 2001. Science 291:319 2. Agata Y, et al. 1996. Int. Immunol. 8:765 3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706 4. Barber DL, et al. 2006. Nature 439:682 5. Keir ME, et al. 2005. J. Immunol. 175:7372 6. Koehn BH. et al. 2008. J Immunol. 181:5313
Gene ID: 18566
UniProt: View information about CD279 on UniProt.org
Clone: 29F.1A12
Regulatory Status: RUO
Other Names: PD-1, Programmed Death-1, PDCD1
Isotype: Rat IgG2a, κ